Enzo

Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.

The firm said that the decline was due to a customer shifting to internalizing genetic ordering, adverse weather, and the loss of an undisclosed commercial payor.  

The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.

The firm said the increase in overall revenues was due largely to a 4 percent increase in clinical labs revenues, while product revenues inched up 1 percent year over year.

The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.

The company said the revenue growth was largely due to double-digit growth in its clinical labs business.

The test is performed on the company's AmpiProbe platform, and the approval expands Enzo's offering of infectious disease tests in New York.

The index gained 1 percent, outperforming the Nasdaq Biotechnology Index, but underperforming the Dow, which gained 2 percent.

The increase was largely due to a 13 percent rise in clinical lab revenues, driven by sales of molecular diagnostic tests, particularly in women's health.

Enzo Biochem, Enzo Life Sciences, and Yale University had originally brought the suit against Life Technologies, now part of Thermo Fisher, in 2004.